PROSTATE CANCER

Prostate cancer gene from the loss, it is pathological in Shanxi Tumor Hospital director Wang Hung-wide applications such as microdissection, from the level of gene detection of prostate cancer origin concluded.

Prostate cancer in cancer mortality in men, lung cancer has been beyond the second one. Because the disease is a combination of multiple genes changed tumor, pathological changes and the clinical performance of a variety show, according to morphology and cell carcinoma lesions of the reasons for the judgment of the traditional methods highly inaccurate, often leads to the treatment of the blind, affecting prognosis.

British scientists discovered a new study, men in a "BRCA2," if the gene variation arising from defects, with the risk of prostate cancer may have suffered four to five times higher.

Britain's "Cancer Research Campaign" organized Yishiduboshi scientists led a group of 173 European and the United States a total of nearly 5,000 family members after the discovery of investigation, "BRCA2" gene variation of men, before the age of 70 suffering from prostate cancer for the possibility ninth, and ordinary men incidence represents only possibility.